Tafolecimab
Highest phase reached
Phase 3
Drug type
Antibody
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Antibody
- Drug name
- Tafolecimab
- ibi 306
- IBI-306
- ibi306
- Ibi306
- IBI306
- immunoglobulin igg2 anti human proprotein convertase subtilisin kexin type 9 human monoclonal ibi306 gamma 2 chain disulfide with human monoclonal ibi306 kappa chain dimer
- IMMUNOGLOBULIN IGG2, ANTI-(HUMAN PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9) (HUMAN MONOCLONAL IBI306 .GAMMA.2-CHAIN), DISULFIDE WITH HUMAN MONOCLONAL IBI306 .KAPPA.-CHAIN, DIMER
- tafolecimab
- Tafolecimab
- tafolecimab (a modified manufacturing process)
- tafolecimab (a original manufacturing process)
- tafolecimab [INN]
- Tafolecimab [WHO-DD]
- tafolecimab inn
- tafolecimab who dd
- CAS registry numbers
- 2225109-03-3
- ChEMBL ID
- CHEMBL4594554
- FDA ingredient codes (UNII)
- KV2ZKH0NIM
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- tafolecimab
- Type
- Antibody
- Drug name stem
- -mab
- Approval recorded by Guide to Pharmacology
- Yes
- Action
- Binding
- Action type
- Binding
- Target
- proprotein convertase subtilisin/kexin type 9
- Gene symbol
- PCSK9
- Protein identifier
- Q8NBP7
- Mechanism
- Subtilisin/kexin type 9 inhibitor
- Action type
- Inhibitor
- Target
- Proprotein convertase subtilisin/kexin type 9
- Protein identifier
- Q8NBP7
Open Targets mechanisms
- Mechanism
- Subtilisin/kexin type 9 inhibitor
- Action type
- Inhibitor
- Target
- Proprotein convertase subtilisin/kexin type 9
- Condition
- Hyperlipoproteinemia Type II
- Highest recorded phase
- 3
- Condition identifier
- EFO:0004911
- Subject identifier
- D006938
- Condition
- Hypercholesterolemia
- Highest recorded phase
- 3
- Condition identifier
- HP:0003124
- Subject identifier
- D006937
- Condition
- Lung Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0008903
- Subject identifier
- D008175
- Condition
- Hyperlipoproteinemia Type II
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0018328
- Subject identifier
- D006938
- Condition identifier
- EFO_0004911
- Highest recorded phase
- 3
- Condition identifier
- HP_0003124
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005233
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005264
- Condition identifier
- MONDO_0005439
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005542
- Condition identifier
- MONDO_0006519
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0008433
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0018328
- Condition identifier
- MONDO_1060198
- Condition identifier
- Orphanet_79211
- Highest recorded phase
- 3
- NCT03366688
- NCT03815812
- NCT04289285
- NCT04709536
- NCT04031742
- NCT04179669
- NCT06421298
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
Related records
Trials (19)
- A Prospective, Single-arm, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Tafolecimab and Sintilimab Combined With Chemotherapy in Patients With Advanced or Metastatic Driver Gene-negative Non-small Cell Lung Cancer After Failure of First-line Immunotherapy.
- A Study of IBI306 in Participants With Hypercholesterolemia
- A Study to Evaluate Safety and Efficacy of IBI306, a PCSK9 Monoclonal Antibody in Chinese Subjects With Homozygous Familial Hypercholesterolemia
- Anti-PCSK9 Antibody Tafolecimab and Anti-PD-1 Antibody Sintilimab Combined With Neoadjuvant Chemoradiotherapy for pMMR/ MSS Locally Advanced Rectal Cancer : A Prospective, Multicenter, Randomized, Open-Label, Parallel-Controlled Trial
- Bioequivalence Study of Tafolecimab Injections in Chinese Healthy Male Volunteers
- Early Initiation of Tafolecimab for Patients With Acute Coronary Syndromeundergoing Percutaneous Coronary Intervention in Chinese Population
- Effectiveness of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Initiation Before Percutaneous Coronary Intervention on Acute Myocardial Infarction Patients
- Evaluate the Efficacy and Safety of IBI306 in Subjects With Homozygous Familial Hypercholesterolemia
- IBI306 Monotherapy in Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia
- INtensive liPid-lowering Therapy for Acute High-risk IntracRanial or Extracranial atheroSclerosis -II (INSPIRES-2)
- Multiple Ascending Dose Study of PCSK-9 Inhibitor (IBI306) in Chinese Patients With Hypercholesterolemia
- PD-1 Combined With Bevacizumab and PCSK-9 Inhibitor in Patients With Advanced NSCLC Who Have Progressed After Anti- PD- 1/L1 Therapy
- Safety and Efficacy of IBI306 in Chinese Subjects With Non-familial Hypercholesterolemia
- Safety and Efficacy of IBI306 in HeFH Patients
- Single Ascending Dose Study of PCSK-9 Inhibitor (IBI306) in Healthy Subjects.
- Sintilimab Combined With Tafolecimab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
- Sun Yat-Sen Treatment Strategy for Enhancing Response in Muscle-invasive Bladder Cancer
- Tafolecimab Combined With Sintilimab and SOX in the Treatment of pMMR/MSS Gastric Cancer
- Tafolecimab in Hyperlipidemia: A Study of Different Dosing Intervals
In development for (3)
- Familial hypercholesterolemia Phase 3
- Homozygous familial hypercholesterolemia Phase 3
- Lung cancer Phase 2
Targets (1)
- PCSK9 Subtilisin/kexin type 9 inhibitor